TNFα阻害剤の世界市場レポート 2025年

TNFα阻害剤の市場規模は、今後数年間で安定した成長が見込まれます。2029年にはCAGR2.2％で475億4,000万米ドルに成長します。予測期間の成長は、高精度ドラッグデリバリー、患者中心主義、免疫療法の進化、市場拡大戦略、個別化医療アプローチに起因すると考えられます。予測期間の主な動向には、実臨床エビデンスの活用、競合療法の採用、市場参入戦略、治療用途の拡大、バイオシミラー競争などが含まれます。

TNFα阻害薬市場の成長は、炎症性腸疾患や乾癬などの炎症性疾患の有病率の増加が牽引しています。TNFα阻害剤は、様々な免疫介在性炎症性疾患の治療薬として、消化器病学、皮膚病学、リウマチ学で広く使用されています。世界的に、炎症性腸疾患（IBD）の有病率は、潰瘍性大腸炎が10万人年当たり0.5～24.5例、クローン病が10万人年当たり0.1～16例です。IBD全体の有病率は10万人当たり年間396例です。その結果、炎症性疾患の罹患率の増加がTNFα阻害剤の需要拡大に寄与し、市場の拡大を促進しています。

高齢者人口の増加は、今後数年間におけるTNFα阻害薬市場の拡大を牽引すると予想されます。65歳以上を高齢者と定義する高齢者人口は、自己免疫疾患に罹患しやすく、血流中の炎症活性が亢進する傾向があります。TNFα阻害剤は、この層の炎症や動脈硬化を抑制する効果が実証されています。例えば、世界保健機関（WHO）が2022年10月に発表した報告書によると、2030年までに世界の6人に1人が60歳以上になると予想されています。さらに2050年には、60歳以上の人口は世界で21億人に達すると予測されています。その結果、老年人口の増加がTNFα阻害剤市場の成長に拍車をかけています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界TNFα阻害剤PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のTNFα阻害剤市場：成長率分析
• 世界のTNFα阻害剤市場の実績：規模と成長, 2019-2024
• 世界のTNFα阻害剤市場の予測：規模と成長, 2024-2029, 2034F
• 世界TNFα阻害剤総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のTNFα阻害剤市場薬物による、実績と予測, 2019-2024, 2024-2029F, 2034F
• レミケード（インフリキシマブ）
• エンブレル（エタネルセプト）
• ヒュミラ（アダリムマブ）
• シムジア（セルトリズマブペゴル）
• シンポニ（ゴリムマブ）
• 世界のTNFα阻害剤市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 皮下
• 静脈内
• その他の投与経路
• 世界のTNFα阻害剤市場：疾患タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 炎症性腸疾患
• 乾癬性関節炎
• 潰瘍性大腸炎（UC）
• 関節リウマチ
• 強直性脊椎炎
• その他の病気の種類

第7章 地域別・国別分析

• 世界のTNFα阻害剤市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のTNFα阻害剤市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• TNFα阻害剤市場：競合情勢
• TNFα阻害剤市場：企業プロファイル
  • HanAll Biopharma Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • Janssen Biotech Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Novartis International AG
• Sanofi SA
• Boehringer Ingelheim International GmbH
• Amgen Inc.
• Sandoz International GmbH
• Cadila Healthcare Limited
• UCB S.A
• Intas Pharmaceuticals Ltd.
• Samsung Bioepis Co. Ltd.
• Celltrion Healthcare Co. Ltd.
• LG Life Sciences Ltd.
• AryoGen Pharmed Co. Ltd.
• EPIRUS Biopharmaceuticals Inc.
• Eli Lilly and Company
• The Bristol-Myers Squibb Company

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• TNFα阻害剤市場2029：新たな機会を提供する国
• TNFα阻害剤市場2029：新たな機会を提供するセグメント
• TNFα阻害剤市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

TNF alpha inhibitors are medications used to address inflammatory conditions such as rheumatoid arthritis (RA), psoriatic arthritis, and juvenile idiopathic arthritis, aiming to diminish or eliminate inflammation. However, the use of TNF inhibitors may elevate the risk of skin cancer, particularly non-melanoma skin cancers such as squamous cell carcinoma.

The primary drugs in the TNF alpha inhibitors market include Remicade (infliximab), Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab pegol), and Simponi (golimumab). Remicade is prescribed for individuals with moderately to severely active Crohn's disease who have not responded to alternative treatments. These medications can be administered through various routes, including oral, subcutaneous, intravenous, among others, and are used to treat a range of conditions such as inflammatory bowel disease, psoriatic arthritis, ulcerative colitis (UC), rheumatoid arthritis, ankylosing spondylitis, and more.

The TNF alpha inhibitors market research report is one of a series of new reports from The Business Research Company that provides TNF alpha inhibitors market statistics, including global market size, regional shares, competitors with a TNF alpha inhibitors market share, detailed TNF alpha inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the TNF alpha inhibitors industry. This TNF alpha inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The TNF alpha inhibitors market size has grown marginally in recent years. It will grow from $43.09 billion in 2024 to $43.57 billion in 2025 at a compound annual growth rate (CAGR) of 1.1%. The growth in the historic period can be attributed to healthcare system integration, physician adoption and prescriptions, patient demand and awareness, advancements in biotechnology, expanded indications.

The TNF alpha inhibitors market size is expected to see steady growth in the next few years. It will grow to $47.54 billion in 2029 at a compound annual growth rate (CAGR) of 2.2%. The growth in the forecast period can be attributed to precision drug delivery, patient-centric focus, immunotherapy evolution, market expansion strategies, personalized medicine approach. Major trends in the forecast period include real-world evidence utilization, adoption of combination therapies, market entry strategies, expanded therapeutic applications, biosimilars competition.

The growth of the TNF alpha inhibitor market is driven by the increasing prevalence of inflammatory diseases such as inflammatory bowel disease and psoriasis. TNF alpha inhibitors find widespread use in gastroenterology, dermatology, and rheumatology for treating various immune-mediated inflammatory conditions. Globally, the prevalence of inflammatory bowel disease (IBD) ranges from 0.5-24.5 cases of ulcerative colitis per 100,000 person-years and 0.1-16 cases of Crohn's disease per 100,000 person-years. The overall IBD prevalence stands at 396 cases per 100,000 people annually. Consequently, the rising incidence of inflammatory diseases contributes to a growing demand for TNF alpha inhibitors, fostering market expansion.

The growing geriatric population is anticipated to drive the expansion of the TNF-alpha inhibitors market in the coming years. The elderly population, defined as individuals aged 65 and older, tends to be more vulnerable to autoimmune disorders and exhibits heightened inflammatory activity in the bloodstream. TNF-alpha inhibitors have demonstrated efficacy in reducing inflammation and atherosclerosis among this demographic. For example, a report released by the World Health Organization (WHO) in October 2022 indicated that by 2030, one in six people globally is expected to be 60 years old or older. Furthermore, by 2050, the number of individuals aged 60 and above is projected to reach 2.1 billion worldwide. Consequently, the increasing geriatric population is fueling the growth of the TNF-alpha inhibitors market.

Companies in the TNF alpha inhibitor market are directing their efforts towards research and development. This focus on R&D enables market players to assess and embrace high-quality research proposals from global sources, aiming to deliver biologically and clinically superior performance that ensures a more comfortable patient experience and faster recovery times. A case in point is MyMD Pharmaceuticals, Inc., a US-based clinical stage pharmaceutical company dedicated to extending healthy lifespans. In February 2022, the company disclosed Phase 1 clinical trial data indicating MYMD-1's capacity to reduce tumor necrosis factor-alpha (TNF-a), the molecules considered the root cause of aging, in the blood of healthy human subjects. MYMD-1 has demonstrated efficacy in pre-clinical studies by regulating the immune system as a selective inhibitor of TNF-a, a driver of chronic inflammation.

Major players in the TNF alpha inhibitor market are also actively engaging in strategic collaborations to expand their product portfolios and make TNF-blockers more widely accessible to patients. Product distribution, in this context, involves dispersing products such as TNF-alpha inhibitors throughout the market for purchase. For instance, in June 2023, Mark Cuban Cost Plus Drug Company, a US-based pharmaceutical company, collaborated with Coherus BioSciences Inc., a US-based biopharmaceutical company. The partnership aimed to provide Mark Cuban Cost Plus Drug Company customers with YUSIMRY (adalimumab-aqvh), a biosimilar of HUMIRA (adalimumab injection), a TNF blocker approved for various conditions. This collaboration is part of Coherus' biosimilar strategy, leveraging its manufacturing and supply chain management capabilities to produce safe and efficient biosimilars with a dependable supply.

In October 2023, Amgen Inc., a US-based biotechnology company, acquired Horizon Therapeutics PLC for $27.8 billion. This acquisition aligns with Amgen's core business objective of offering groundbreaking medications that significantly improve the lives of patients with critical diseases. Horizon Therapeutics PLC, a US-based biopharmaceutical company, is involved in developing and marketing TNF inhibitors for treating rheumatoid arthritis (RA).

Major companies operating in the TNF alpha inhibitors market include HanAll Biopharma Co. Ltd., Pfizer Inc., Johnson & Johnson, Janssen Biotech Inc., AbbVie Inc., Novartis International AG, Sanofi SA, Boehringer Ingelheim International GmbH, Amgen Inc., Sandoz International GmbH, Cadila Healthcare Limited, UCB S.A, Intas Pharmaceuticals Ltd., Samsung Bioepis Co. Ltd., Celltrion Healthcare Co. Ltd., LG Life Sciences Ltd., AryoGen Pharmed Co. Ltd., EPIRUS Biopharmaceuticals Inc., Eli Lilly and Company, The Bristol-Myers Squibb Company, Mylan N.V., Teva Pharmaceutical Industries Ltd., Apotex Inc.

North America was the largest region in the TNF alpha inhibitors market in 2024. The regions covered in the tnf alpha inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the tnf alpha inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The TNF alpha inhibitors market consists of sales of infliximab, adalimumab, etanercept, golimumab, and certolizumab. Values in this market are "factory gate values," that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

TNF Alpha Inhibitors Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on tnf alpha inhibitors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for tnf alpha inhibitors ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The tnf alpha inhibitors market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug: Remicade (Infliximab); Enbrel (Etanercept); Humira (Adalimumab); Cimzia (Certolizumab Pegol); Simponi (Golimumab)
• 2) By Route Of Administration: Oral; Subcutaneous; Intravenous; Other Route Of Administration
• 3) By Disease Type: Inflammatory Bowel Disease; Psoriatic Arthritis; Ulcerative Colitis (UC); Rheumatoid Arthritis; Ankylosing Spondylitis; Other Disease Types
• Companies Mentioned: HanAll Biopharma Co. Ltd.; Pfizer Inc.; Johnson & Johnson; Janssen Biotech Inc.; AbbVie Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. TNF Alpha Inhibitors Market Characteristics

3. TNF Alpha Inhibitors Market Trends And Strategies

4. TNF Alpha Inhibitors Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global TNF Alpha Inhibitors Growth Analysis And Strategic Analysis Framework

• 5.1. Global TNF Alpha Inhibitors PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global TNF Alpha Inhibitors Market Growth Rate Analysis
• 5.4. Global TNF Alpha Inhibitors Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global TNF Alpha Inhibitors Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global TNF Alpha Inhibitors Total Addressable Market (TAM)

6. TNF Alpha Inhibitors Market Segmentation

• 6.1. Global TNF Alpha Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Remicade (Infliximab)
• Enbrel (Etanercept)
• Humira (Adalimumab)
• Cimzia (Certolizumab Pegol)
• Simponi (Golimumab)
• 6.2. Global TNF Alpha Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Subcutaneous
• Intravenous
• Other Route Of Administration
• 6.3. Global TNF Alpha Inhibitors Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Inflammatory Bowel Disease
• Psoriatic Arthritis
• Ulcerative Colitis (UC)
• Rheumatoid Arthritis
• Ankylosing Spondylitis
• Other Disease Types

7. TNF Alpha Inhibitors Market Regional And Country Analysis

• 7.1. Global TNF Alpha Inhibitors Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global TNF Alpha Inhibitors Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific TNF Alpha Inhibitors Market

• 8.1. Asia-Pacific TNF Alpha Inhibitors Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific TNF Alpha Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific TNF Alpha Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific TNF Alpha Inhibitors Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China TNF Alpha Inhibitors Market

• 9.1. China TNF Alpha Inhibitors Market Overview
• 9.2. China TNF Alpha Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China TNF Alpha Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China TNF Alpha Inhibitors Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India TNF Alpha Inhibitors Market

• 10.1. India TNF Alpha Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India TNF Alpha Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India TNF Alpha Inhibitors Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan TNF Alpha Inhibitors Market

• 11.1. Japan TNF Alpha Inhibitors Market Overview
• 11.2. Japan TNF Alpha Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan TNF Alpha Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan TNF Alpha Inhibitors Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia TNF Alpha Inhibitors Market

• 12.1. Australia TNF Alpha Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia TNF Alpha Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia TNF Alpha Inhibitors Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia TNF Alpha Inhibitors Market

• 13.1. Indonesia TNF Alpha Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia TNF Alpha Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia TNF Alpha Inhibitors Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea TNF Alpha Inhibitors Market

• 14.1. South Korea TNF Alpha Inhibitors Market Overview
• 14.2. South Korea TNF Alpha Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea TNF Alpha Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea TNF Alpha Inhibitors Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe TNF Alpha Inhibitors Market

• 15.1. Western Europe TNF Alpha Inhibitors Market Overview
• 15.2. Western Europe TNF Alpha Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe TNF Alpha Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe TNF Alpha Inhibitors Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK TNF Alpha Inhibitors Market

• 16.1. UK TNF Alpha Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK TNF Alpha Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK TNF Alpha Inhibitors Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany TNF Alpha Inhibitors Market

• 17.1. Germany TNF Alpha Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany TNF Alpha Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany TNF Alpha Inhibitors Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France TNF Alpha Inhibitors Market

• 18.1. France TNF Alpha Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France TNF Alpha Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France TNF Alpha Inhibitors Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy TNF Alpha Inhibitors Market

• 19.1. Italy TNF Alpha Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy TNF Alpha Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy TNF Alpha Inhibitors Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain TNF Alpha Inhibitors Market

• 20.1. Spain TNF Alpha Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain TNF Alpha Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain TNF Alpha Inhibitors Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe TNF Alpha Inhibitors Market

• 21.1. Eastern Europe TNF Alpha Inhibitors Market Overview
• 21.2. Eastern Europe TNF Alpha Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe TNF Alpha Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe TNF Alpha Inhibitors Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia TNF Alpha Inhibitors Market

• 22.1. Russia TNF Alpha Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia TNF Alpha Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia TNF Alpha Inhibitors Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America TNF Alpha Inhibitors Market

• 23.1. North America TNF Alpha Inhibitors Market Overview
• 23.2. North America TNF Alpha Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America TNF Alpha Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America TNF Alpha Inhibitors Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA TNF Alpha Inhibitors Market

• 24.1. USA TNF Alpha Inhibitors Market Overview
• 24.2. USA TNF Alpha Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA TNF Alpha Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA TNF Alpha Inhibitors Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada TNF Alpha Inhibitors Market

• 25.1. Canada TNF Alpha Inhibitors Market Overview
• 25.2. Canada TNF Alpha Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada TNF Alpha Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada TNF Alpha Inhibitors Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America TNF Alpha Inhibitors Market

• 26.1. South America TNF Alpha Inhibitors Market Overview
• 26.2. South America TNF Alpha Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America TNF Alpha Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America TNF Alpha Inhibitors Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil TNF Alpha Inhibitors Market

• 27.1. Brazil TNF Alpha Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil TNF Alpha Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil TNF Alpha Inhibitors Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East TNF Alpha Inhibitors Market

• 28.1. Middle East TNF Alpha Inhibitors Market Overview
• 28.2. Middle East TNF Alpha Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East TNF Alpha Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East TNF Alpha Inhibitors Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa TNF Alpha Inhibitors Market

• 29.1. Africa TNF Alpha Inhibitors Market Overview
• 29.2. Africa TNF Alpha Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa TNF Alpha Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa TNF Alpha Inhibitors Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. TNF Alpha Inhibitors Market Competitive Landscape And Company Profiles

• 30.1. TNF Alpha Inhibitors Market Competitive Landscape
• 30.2. TNF Alpha Inhibitors Market Company Profiles
  • 30.2.1. HanAll Biopharma Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Janssen Biotech Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. TNF Alpha Inhibitors Market Other Major And Innovative Companies

• 31.1. Novartis International AG
• 31.2. Sanofi SA
• 31.3. Boehringer Ingelheim International GmbH
• 31.4. Amgen Inc.
• 31.5. Sandoz International GmbH
• 31.6. Cadila Healthcare Limited
• 31.7. UCB S.A
• 31.8. Intas Pharmaceuticals Ltd.
• 31.9. Samsung Bioepis Co. Ltd.
• 31.10. Celltrion Healthcare Co. Ltd.
• 31.11. LG Life Sciences Ltd.
• 31.12. AryoGen Pharmed Co. Ltd.
• 31.13. EPIRUS Biopharmaceuticals Inc.
• 31.14. Eli Lilly and Company
• 31.15. The Bristol-Myers Squibb Company

32. Global TNF Alpha Inhibitors Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The TNF Alpha Inhibitors Market

34. Recent Developments In The TNF Alpha Inhibitors Market

35. TNF Alpha Inhibitors Market High Potential Countries, Segments and Strategies

• 35.1 TNF Alpha Inhibitors Market In 2029 - Countries Offering Most New Opportunities
• 35.2 TNF Alpha Inhibitors Market In 2029 - Segments Offering Most New Opportunities
• 35.3 TNF Alpha Inhibitors Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer